CLOs on the Move

ViaCyte

www.viacyte.com

 
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.viacyte.com
  • 3550 General Atomics Court
    San Diego, CA USA 92121
  • Phone: 858.207.0500

Executives

Name Title Contact Details
Marty Lorenzo
 General Counsel Profile

Similar Companies

AltheaDx

AltheaDx, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. AltheaDx, Inc. is based in San Diego, CA. You can find more information on AltheaDx, Inc. at www.altheadx.com

Expansion Therapeutics

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.

Bioduro-Sundia

BioDuro-Sundia provide its biopharma customers a single end-to-end solution from early stage drug discovery to late stage manufacturing.

Manifold Bio

A next-generation protein therapeutics company pioneering an in vivo biologics design platform. By redesigning in vivo measurement to be available from day one, Manifold Bio has an advantage in solving complex biologic challenges.

Nurix Therapeutics

Nurix Therapeutics discovers drugs that harness the body`s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.